Cytogen, Inc. (KOSDAQ:217330)
South Korea · Delayed Price · Currency is KRW 4,585.00
-85.00 (-1.82%)
At close: May 20, 2026
Cytogen Revenue
In the year 2025, Cytogen had annual revenue of 26.05B KRW with 138.80% growth. Cytogen had revenue of 6.55B in the quarter ending December 31, 2025, with 17.21% growth.
Revenue
26.05B
Revenue Growth
+138.80%
P/S Ratio
4.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
106.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.05B | 15.14B | 138.80% |
| Dec 31, 2024 | 10.91B | 7.73B | 242.63% |
| Dec 31, 2023 | 3.18B | 2.42B | 318.57% |
| Dec 31, 2022 | 760.78M | 412.93M | 118.71% |
| Dec 31, 2021 | 347.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The Nature Holdings | 477.52B |
| XEXYMIX | 274.10B |
| Osang Healthcare Co.,Ltd | 128.63B |
| Foodnamoo. | 86.81B |
| Viatron Technologies | 65.12B |
| Sewoon Medical | 63.66B |
| NFC Corporation | 34.07B |
| Aminologics | 22.02B |